Arrowhead Pharmaceuticals Reports Fiscal 2018 Third Quarter Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Arrowhead Pharmaceuticals Reports Fiscal 2018 Third Quarter Results

Arrowhead Research (ARWR) PT Raised to $18 at Cantor Fitzgerald

August 8, 2018 6:58 AM EDT

Cantor Fitzgerald raised its price target on Arrowhead Research (NASDAQ: ARWR) to $18.00 (from $13.00) while maintaining a Overweight rating following 3Q18 financial and corporate updates.

Analyst Elemer Piros commented, "The company hosted a call and highlighted upcoming data presentations at AASLD (pending abstract... More

Arrowhead Research (ARWR) PT Raised to $17.50 at Chardan Capital Markets

August 8, 2018 6:55 AM EDT

Chardan Capital Markets raised its price target on Arrowhead Research (NASDAQ: ARWR) to $17.50 (from $16.00) while maintaining a Buy rating.

... More

Arrowhead Pharmaceuticals Corp (ARWR) Reports In-Line Q3 EPS, Revenues Beat

August 7, 2018 4:00 PM EDT

Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q3 EPS of ($0.18), in-line with the analyst estimate of ($0.18). Revenue for the quarter came in at $727.38 thousand versus the consensus estimate of $690 thousand.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.

... More